LPA receptor antagonists and uses thereof
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
1. A compound that is of the formula:
or a pharmaceutically acceptable salt thereof.
2. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
3. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
4. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
5. A compound of the formula:
or a pharmaceutically acceptable salt thereof.